Agnieszka Wieclawek

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
AIM OF THE STUDY Mutant NPM1 and CEBPA have been reported in patients with acute myeloid leukaemia (AML) and intermediate cytogenetic risk, and they appear to be associated with characteristic demographic and laboratory data, as well as clinical outcome. The objective of the study was to assess the clinical relevance of NPM1 and CEBPA mutations in AML. (More)
  • 1